Quest for the right Drug
פלבוגאמה % 5 דיפ FLEBOGAMMA 5 % DIF (IMMUNOGLOBULINS, NORMAL HUMAN)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה לאינפוזיה : SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Summary of the safety profile Adverse reactions caused by human normal immunoglobulins (in decreasing frequency) encompass (see also Section 4.4): • chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain • reversible haemolytic reactions; especially in those patients with blood groups A, B, and AB and (rarely) haemolytic anaemia requiring transfusion • (rarely) a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration • (rarely) transient cutaneous reactions (including cutaneous lupus erythematosus - frequency unknown) • (very rarely) thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses • cases of reversible aseptic meningitis • cases of increased serum creatinine level and/or occurrence of acute renal failure • cases of Transfusion Related Acute Lung Injury (TRALI) For safety information with respect to transmissible agents, see section 4.4. Tabulated list of adverse reactions The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: - very common (>1/10) - common (>1/100 to <1/10) - uncommon (>1/1,000 to <1/100) - rare (>1/10,000 to <1/1,000) - very rare (<1/10,000) - not known (cannot be estimated from the available data) Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Source of the safety database from clinical trials and post-authorisation safety studies in a total of 128 patients exposed to Flebogamma 5% DIF (with a total of 1318 infusions) Frequency Frequency MedDRA System Organ Adverse reaction per per Class (SOC) patient infusion Infections and infestations Nasopharyngitis Uncommon Uncommon Immune system disorders Hypersensitivity Uncommon Rare Psychiatric disorders Abnormal behaviour Uncommon Rare Migraine Uncommon Rare Very Nervous system disorders Headache Common Common Dizziness Common Uncommon Tachycardia Common Common Cardiac disorders Cardiovascular disorder Uncommon Rare Hypertension Common Uncommon Diastolic hypertension Common Uncommon Systolic hypertension Uncommon Uncommon Vascular disorders Hypotension Common Common Diastolic hypotension Common Common Blood pressure fluctuation Uncommon Rare Flushing Uncommon Rare Bronchitis Common Uncommon Dyspnoea Uncommon Rare Asthma Uncommon Rare Epistaxis Uncommon Rare Respiratory, thoracic and Productive cough Uncommon Uncommon mediastinal disorders Cough Uncommon Rare Wheezing Common Uncommon Laryngeal pain Uncommon Rare Nasal discomfort Uncommon Rare Diarrhoea Common Uncommon Vomiting Common Uncommon Gastrointestinal disorders Abdominal pain upper Common Uncommon Abdominal pain Common Uncommon Nausea Common Uncommon Rash pruritic Uncommon Uncommon Dermatitis contact Uncommon Rare Skin and subcutaneous Urticaria Common Uncommon tissue disorders Pruritus Uncommon Uncommon Rash Uncommon Rare Hyperhidrosis Uncommon Rare Arthralgia Common Uncommon Musculoskeletal and Myalgia Common Uncommon connective tissue disorders Back pain Common Uncommon Frequency Frequency MedDRA System Organ Adverse reaction per per Class (SOC) patient infusion Neck pain Uncommon Rare Pain in extremity Uncommon Rare Muscle spasms Uncommon Rare Renal and urinary disorders Urinary retention Uncommon Rare Very Pyrexia Common Common Chest pain Uncommon Rare Oedema peripheral Uncommon Rare Chills Common Uncommon Rigors Common Uncommon Pain Common Uncommon General disorders and Asthenia Uncommon Rare administration site Injection site reaction Common Uncommon conditions Infusion site erythema Uncommon Rare Infusion site extravasation Uncommon Rare Injection site pruritus Uncommon Rare Infusion site inflammation Uncommon Rare Injection site swelling Uncommon Rare Injection site oedema Uncommon Rare Infusion site pain Uncommon Rare Injection site pain Uncommon Rare Blood pressure increased Uncommon Rare Blood pressure systolic increased Common Uncommon Blood pressure systolic decreased Uncommon Uncommon Investigations Body temperature increased Common Uncommon Alanine aminotransferase Uncommon Rare increased Coombs test positive Common Uncommon Injury, poisoning and Infusion related reaction Uncommon Uncommon procedural complications Description of selected adverse reactions The most reported post-marketing ADRs received since the product was authorised for both concentrations were chest pain, flushing, blood pressure increased and decreased, malaise, dyspnoea, nausea, vomiting, pyrexia, back pain, headache and chills. Paediatric population The safety results for 29 paediatric patients (those ≤ 17 years old) included in the PID studies were evaluated. It was observed that the proportion of headache, pyrexia, tachycardia and hypotension in children was higher than in adults. Assessment of vital signs in clinical trials of the paediatric population did not indicate any pattern of clinically relevant changes. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health (www.health.gov.il) according to the National Regulation by using an online form https://sideeffects.health.gov.il
פרטי מסגרת הכללה בסל
התרופה תינתן לטיפול במקרים האלה: א. חסר חיסוני ראשוני (חולים עם פגיעה ראשונית בייצור נוגדנים כגון אגמגלובולינמיה או היפוגמגלובוילינמיה, ITP (Idiopathic thrombocytopenic purpura)); ב. חסר חיסוני ספציפי, מניעה או טיפול בחצבת, הפטיטיס A ויראלית; ג. CIDP – Chronic inflammatory demyelineating polyneuropathy; ד.טיפול בחולי לוקמיה מסוג CLL הסובלים מהיפוגלמגלובולינמיה משנית חמורה וזיהומים חוזרים.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
טיפול בחולי לוקמיה מסוג CLL הסובלים מהיפוגלמגלובולינמיה משנית חמורה וזיהומים חוזרים. | 01/01/1995 | |||
CIDP – Chronic inflammatory demyelineating polyneuropathy; | 01/01/1995 | |||
חסר חיסוני ספציפי, מניעה או טיפול בחצבת, הפטיטיס A ויראלית | 01/01/1995 | |||
חסר חיסוני ראשוני (חולים עם פגיעה ראשונית בייצור נוגדנים כגון אגמגלובולינמיה או היפוגמגלובולינמיה, ITP (Idiopathic thrombocytopenic purpura)); | 01/01/1995 |
שימוש לפי פנקס קופ''ח כללית 1994
Primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinemia or hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP)
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
מידע נוסף